Back

New onset atrial fibrillation in st-segment elevation myocardial infarction: predictors and impact on therapy and mortality

30 August 2016 (09:24 - 09:42)
Organised by:
Congress Presentation Part of: Challenges with anticoagulants and antithrombotics in acute coronary syndrome Infarction acute phase STEMI ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Kisa Hyde Congo

Hospital Espirito Santo de Evora, Evora (Portugal)

4 More presentations in this session

Presentation thumbnail
State of the art in treatment of acute coronary syndrome patients in need of oral anticoagulation.
Doctor W. Dewilde (Bonheiden, BE)
Slides Video
Presentation thumbnail
Comparative impact of preexisting and new-onset atrial fibrillation on long-term mortality in STEMI patients admitted for primary PCI
Doctor I. Veljic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Incidence, presentation, treatment and outcome of patients with myocardial infarction type 2 in routine clinical practice
Doctor D. Radovanovic (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Future direction for research in treatment of acute coronary syndrome patients in need of oral anticoagulation.
Doctor M. Lettino (Monza, IT)
Slides Video

Access the full session

Session thumbnail
Challenges with anticoagulants and antithrombotics in acute coronary syndrome

The Event

Event poster

ESC Congress 2016

30 August 2016 09:24 CET
You may be interested in
thumbnail
Congress Presentation
Early vs late new-onset atrial fibrillation in STEMI patients: pathophysiological mechanisms and relationship with in-hospital outcomes
27 August 2021
thumbnail
Webinar
ACVC Biomarker Talk Series - Biomarkers in atrial fibrillation
24 November 2021
thumbnail
Congress Presentation
Predictors and outcomes of electrical storm in patients with sustained ventricular arrhythmias during acute myocardial infarction
13 April 2026
thumbnail
Congress Presentation
Management and impact of atrial fibrillation in the COVID 19 era; concomitancy of two procoagulant phenomena
29 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources